{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.1057","meta":{"versionId":"5","lastUpdated":"2022-03-01T14:50:45.000-05:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"NCQA PHEMUR Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2022-03-01"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1057","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.464.1003.1057"}],"version":"20210909","name":"CentralNervousSystemOther","title":"Central nervous system, other","status":"active","experimental":false,"date":"2021-09-09T01:01:23-04:00","publisher":"NCQA PHEMUR","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts for meprobamate medications.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent generic, human use and prescribable medications.),(Exclusion Criteria: Excludes concepts that represent non-prescribable or branded drugs and excludes concepts that represent components or ingredients.)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1256"]}]},"expansion":{"identifier":"urn:uuid:b1c7f596-d69d-4d86-904a-cfaa00d5b55d","timestamp":"2023-12-11T02:05:09-05:00","total":2,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"197928","display":"meprobamate 200 MG Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"197929","display":"meprobamate 400 MG Oral Tablet"}]}}